Expanded Access Protocol Submitted to the FDA – March 2019

In March 2019, MAPS Public Benefit Corporation (MAPS PBC) received a clinical hold letter from the U.S. Food and Drug Administration (FDA) regarding the submitted protocol for an Expanded Access program for MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD). The clinical hold letter will delay the proposed clinical research.